PHBI — Pharmagreen Biotech Income Statement
0.000.00%
Last trade - 00:00- $0.86m
- $1.17m
- $0.00m
Annual income statement for Pharmagreen Biotech, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | ARS | ARS |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0.003 | 0.003 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | 0.001 | 0.002 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 0.661 | 0.515 | 1.01 | 0.451 | 0.249 |
| Operating Profit | -0.661 | -0.515 | -1.01 | -0.448 | -0.246 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -2.48 | -4.53 | -0.876 | -0.569 | -1 |
| Net Income After Taxes | -2.48 | -4.53 | -0.876 | -0.569 | -1 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -2.44 | -4.53 | -0.875 | -0.569 | -1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2.44 | -4.53 | -0.875 | -0.569 | -1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.024 | -0.016 | -0.002 | -0.001 | -0.002 |